Lifeline for ALK cancer patients: continued access to targeted therapy
NCT ID NCT02584933
First seen Sep 30, 2025 · Last updated May 21, 2026 · Updated 31 times
Summary
This study offers ongoing treatment with the drug ceritinib to people with ALK-positive cancers who were already benefiting from it in a previous Novartis study. The goal is to keep providing the medicine and monitor its long-term safety. About 233 participants will take part, and they must have followed the rules of the earlier study and still be expected to benefit from continued treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALK POSITIVE MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Essex Oncology of North Jersey PA
Belleville, New Jersey, 07109, United States
-
Highlands Oncology Group
Fayetteville, Arkansas, 72703, United States
-
Loma Linda University
Loma Linda, California, 92354, United States
-
Maryland Oncology Hematology P A
Rockville, Maryland, 20850, United States
-
Novartis Investigative Site
Melbourne, Victoria, 3000, Australia
-
Novartis Investigative Site
Auckland, 1023, Australia
-
Novartis Investigative Site
Leuven, 3000, Belgium
-
Novartis Investigative Site
Natal, Rio Grande do Norte, 59075 740, Brazil
-
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, 90610-000, Brazil
-
Novartis Investigative Site
Barretos, São Paulo, 14784 400, Brazil
-
Novartis Investigative Site
São Paulo, São Paulo, 01246 000, Brazil
-
Novartis Investigative Site
Sofia, 1303, Bulgaria
-
Novartis Investigative Site
Guangzhou, Guangdong, 510080, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510120, China
-
Novartis Investigative Site
Changchun, Jilin, 130012, China
-
Novartis Investigative Site
Beijing, 100039, China
-
Novartis Investigative Site
Guangzhou, 510060, China
-
Novartis Investigative Site
Montería, 230004, Colombia
-
Novartis Investigative Site
Brno, 656 53, Czechia
-
Novartis Investigative Site
Paris, 75231, France
-
Novartis Investigative Site
Paris, 75970, France
-
Novartis Investigative Site
Saint-Herblain, 44805, France
-
Novartis Investigative Site
Strasbourg, 67091, France
-
Novartis Investigative Site
Villejuif, 94800, France
-
Novartis Investigative Site
Regensburg, Bavaria, 93053, Germany
-
Novartis Investigative Site
Cologne, North Rhine-Westphalia, 50937, Germany
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Heidelberg, 69120, Germany
-
Novartis Investigative Site
Würzburg, 97074, Germany
-
Novartis Investigative Site
Hong Kong, 999077, Hong Kong
-
Novartis Investigative Site
Bergamo, BG, 24127, Italy
-
Novartis Investigative Site
Bologna, BO, 40138, Italy
-
Novartis Investigative Site
Brescia, BS, 25123, Italy
-
Novartis Investigative Site
Meldola, FC, 47014, Italy
-
Novartis Investigative Site
Monza, MB, 20900, Italy
-
Novartis Investigative Site
Milan, MI, 20133, Italy
-
Novartis Investigative Site
Milan, MI, 20162, Italy
-
Novartis Investigative Site
Rozzano, MI, 20089, Italy
-
Novartis Investigative Site
Modena, MO, 41124, Italy
-
Novartis Investigative Site
Perugia, PG, 06129, Italy
-
Novartis Investigative Site
Aviano, PN, 33081, Italy
-
Novartis Investigative Site
Milan, 20141, Italy
-
Novartis Investigative Site
Naples, 80131, Italy
-
Novartis Investigative Site
Novara, 28100, Italy
-
Novartis Investigative Site
Nagoya, Aichi-ken, 464 8681, Japan
-
Novartis Investigative Site
Fukuoka, Fukuoka, 811-1395, Japan
-
Novartis Investigative Site
Akashi, Hyōgo, 673-8558, Japan
-
Novartis Investigative Site
Koto Ku, Tokyo, 135-8550, Japan
-
Novartis Investigative Site
Beirut, 166830, Lebanon
-
Novartis Investigative Site
George Town, Pulau Pinang, 10450, Malaysia
-
Novartis Investigative Site
Kuching, Sarawak, 93586, Malaysia
-
Novartis Investigative Site
Gdansk, 80-214, Poland
-
Novartis Investigative Site
Moscow, 115522, Russia
-
Novartis Investigative Site
Saint Petersburg, 192148, Russia
-
Novartis Investigative Site
Saint Petersburg, 197343, Russia
-
Novartis Investigative Site
Singapore, 168583, Singapore
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Seoul, 03722, South Korea
-
Novartis Investigative Site
Seoul, 05505, South Korea
-
Novartis Investigative Site
A Coruña, 15006, Spain
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Novartis Investigative Site
Madrid, 28046, Spain
-
Novartis Investigative Site
Madrid, 28050, Spain
-
Novartis Investigative Site
Málaga, 29010, Spain
-
Novartis Investigative Site
Taichung, 40447, Taiwan
-
Novartis Investigative Site
Taichung, 407219, Taiwan
-
Novartis Investigative Site
Taipei, 10002, Taiwan
-
Novartis Investigative Site
Taipei, 110, Taiwan
-
Novartis Investigative Site
Taipei, 11217, Taiwan
-
Novartis Investigative Site
Taoyuan, 33305, Taiwan
-
University of Colorado Cancer Center
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.